👍-To The Moon - Tiger Brokers Online Investing Community - To The Moon

3
Comment
Favorite

興旺發丫
2022-04-25

👍

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play

Tigermed’s high growth and high valuation are inseparable from continuous M&As and investment. However, uncertain macro environment and risk of recession question if "CRO+PE/VC" model is a safe play. Despite solid growth in 2021, if seen from prior years, the revenue YoY growth rate and net profit YoY growth rate showed a state of divergence, which is “interesting”. Since half of Tigermed’s net profits were from investment income,it’s not logical to apply the valuation methods of traditional CXO to Tigermed. Its CRO and investment should be valued separately. The poor IPO sentiment, risk of recession and the domestic healthcare rational return would make investors reconsider if Tigermed’s “CRO + PE/VC business model” would be a safe play. By Xinyao (Criss) Wang - https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Hangzhou Tigermed Consulting (H) (3347 HK) - https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff?utm_source=tiger_community

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

3

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9084605793,"tweetId":"9084605793","gmtCreate":1650852392937,"gmtModify":1676534803476,"author":{"id":3574070203715316,"idStr":"3574070203715316","authorId":3574070203715316,"authorIdStr":"3574070203715316","name":"興旺發丫","avatar":"https://static.tigerbbs.com/e4dd3df5958287045f11520c7370bb40","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9084605793","repostId":9084867912,"repostType":1,"repost":{"magic":2,"id":9084867912,"tweetId":"9084867912","gmtCreate":1650847356000,"gmtModify":1676534802278,"author":{"id":4103332230805300,"idStr":"4103332230805300","authorId":4103332230805300,"authorIdStr":"4103332230805300","name":"Smartkarma","avatar":"https://community-static.tradeup.com/news/39fffba2ff205c2730b5bf07e3de6647","vip":5,"userType":5,"introduction":"https://on.skr.ma/free4tiger","boolIsFan":false,"boolIsHead":false,"crmLevel":0,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1808,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play","extraTitle":"","html":"<html><head></head><body><p><b>Tigermed’s&nbsp;high growth and high valuation are inseparable from continuous M&amp;As and investment.&nbsp;However, uncertain macro environment and risk of recession question if &nbsp;\"CRO+PE/VC\" model is a safe play.</b></p> <ul> \n <li>Despite solid growth in 2021, if seen from prior years, the revenue YoY growth rate and net profit YoY growth rate showed a state of divergence, which is “interesting”.</li> \n <li>Since half of Tigermed’s net profits were from investment income,it’s not logical to apply the valuation methods of traditional CXO to Tigermed. Its CRO and investment should be valued separately.</li> \n <li>The poor IPO sentiment, risk of recession and the domestic healthcare rational return would make investors reconsider if Tigermed’s “CRO + PE/VC business model” would be a safe play.</li> \n</ul> <p>By Xinyao (Criss) Wang - https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community</p> <p>On Hangzhou Tigermed Consulting (H) (3347 HK) - https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff?utm_source=tiger_community</p></body></html>","htmlText":"<html><head></head><body><p><b>Tigermed’s&nbsp;high growth and high valuation are inseparable from continuous M&amp;As and investment.&nbsp;However, uncertain macro environment and risk of recession question if &nbsp;\"CRO+PE/VC\" model is a safe play.</b></p> <ul> \n <li>Despite solid growth in 2021, if seen from prior years, the revenue YoY growth rate and net profit YoY growth rate showed a state of divergence, which is “interesting”.</li> \n <li>Since half of Tigermed’s net profits were from investment income,it’s not logical to apply the valuation methods of traditional CXO to Tigermed. Its CRO and investment should be valued separately.</li> \n <li>The poor IPO sentiment, risk of recession and the domestic healthcare rational return would make investors reconsider if Tigermed’s “CRO + PE/VC business model” would be a safe play.</li> \n</ul> <p>By Xinyao (Criss) Wang - https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community</p> <p>On Hangzhou Tigermed Consulting (H) (3347 HK) - https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff?utm_source=tiger_community</p></body></html>","text":"Tigermed’s high growth and high valuation are inseparable from continuous M&As and investment. However, uncertain macro environment and risk of recession question if \"CRO+PE/VC\" model is a safe play. Despite solid growth in 2021, if seen from prior years, the revenue YoY growth rate and net profit YoY growth rate showed a state of divergence, which is “interesting”. Since half of Tigermed’s net profits were from investment income,it’s not logical to apply the valuation methods of traditional CXO to Tigermed. Its CRO and investment should be valued separately. The poor IPO sentiment, risk of recession and the domestic healthcare rational return would make investors reconsider if Tigermed’s “CRO + PE/VC business model” would be a safe play. By Xinyao (Criss) Wang - https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community On Hangzhou Tigermed Consulting (H) (3347 HK) - https://www.smartkarma.com/entities/hangzhou-tigermed-consulting-co-ltd-1008d609-73bd-4d76-8315-b29502a448ff?utm_source=tiger_community","highlighted":2,"essential":1,"paper":2,"link":"https://ttm.financial/post/9084867912","repostId":0,"isVote":1,"tweetType":1,"commentLimit":10,"symbols":["03347"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":907,"xxTargetLangEnum":"ORIG"},"isVote":1,"tweetType":1,"viewCount":741,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}